Clinical imaging · 2026
Diagnostic accuracy of central vein sign on MRI in pediatric-onset multiple sclerosis: A systematic review and meta-analysis.
СтатьяСистематический обзорМетаанализНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Al Dabssi Omar, Kashbour Muataz, Qafesha Ruaa Mustafa, Amro Sarah, Elbadry Menna, Sharabati Israa, Dervis Muhiddin, Khadra Hala
Аннотация
BACKGROUND: Diagnosing multiple sclerosis (MS) in children is challenging due to overlap with other demyelinating disorders. The Central Vein Sign (CVS) is a promising MRI biomarker in adult MS, but its diagnostic role in pediatric-onset MS (POMS) remains unclear. This systematic review and meta-analysis provides the first focused evaluation of CVS accuracy in POMS diagnosis.
PURPOSE: To systematically evaluate prevalence and diagnostic accuracy of the central vein sign in POMS.
METHODS: Followed PRISMA-DTA guidelines, a systematic search was performed on publicly available databases (PubMed, Embase, and Scopus) up to November 2024. Studies measuring the CVS accuracy on MRI in POMS patients were included. Meta-analysis using Open Meta-Analyst software calculated pooled proportions of CVS positivity per patient, per lesion number, the CVS mean positive rate, and lesion distribution patterns across different brain regions.
RESULTS: Five studies (n = 128; mean age 11.4-15.6 years, 34,4% male, disease duration 0.8-1.6 years) met inclusion criteria, of which four (n = 118) were eligible for meta-analysis. The pooled proportion of CVS-positive patients was 0.643 (95% CI: 0.253 to 1.032, p < 0.001), and the pooled number of CVS-positive lesions was 13.851 (95% CI: 11.260 to 16.442, p = 0.829). The mean of the CVS-positive rate ratio was 0.531 (95% CI: 0.346 to 0.715, p < 0.001). Regional analysis revealed the highest CVS lesion burden in periventricular regions (mean = 4.62, 95% CI: 3.39-5.85, p = 0.249).
CONCLUSION: This systematic review and meta-analysis suggests that the central vein sign could be of diagnostic value in POMS, but pediatric-specific criteria are needed. Further prospective studies with standardized imaging are required to establish the role of CVS in differentiating POMS from other demyelinating disorders.
PURPOSE: To systematically evaluate prevalence and diagnostic accuracy of the central vein sign in POMS.
METHODS: Followed PRISMA-DTA guidelines, a systematic search was performed on publicly available databases (PubMed, Embase, and Scopus) up to November 2024. Studies measuring the CVS accuracy on MRI in POMS patients were included. Meta-analysis using Open Meta-Analyst software calculated pooled proportions of CVS positivity per patient, per lesion number, the CVS mean positive rate, and lesion distribution patterns across different brain regions.
RESULTS: Five studies (n = 128; mean age 11.4-15.6 years, 34,4% male, disease duration 0.8-1.6 years) met inclusion criteria, of which four (n = 118) were eligible for meta-analysis. The pooled proportion of CVS-positive patients was 0.643 (95% CI: 0.253 to 1.032, p < 0.001), and the pooled number of CVS-positive lesions was 13.851 (95% CI: 11.260 to 16.442, p = 0.829). The mean of the CVS-positive rate ratio was 0.531 (95% CI: 0.346 to 0.715, p < 0.001). Regional analysis revealed the highest CVS lesion burden in periventricular regions (mean = 4.62, 95% CI: 3.39-5.85, p = 0.249).
CONCLUSION: This systematic review and meta-analysis suggests that the central vein sign could be of diagnostic value in POMS, but pediatric-specific criteria are needed. Further prospective studies with standardized imaging are required to establish the role of CVS in differentiating POMS from other demyelinating disorders.